Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

HC Andersen Capital Events 17/02: Mød topledelsen i Bavarian Nordic

HC Andersen Capital afholder i dag et spændende event, hvor du kan møde og stille spørgsmål direkte til topledelsen. Det er frit for alle og gratis at deltage.Bavarian Nordic - Manifesterer sig som en førende aktør indenfor rejsevacciner, 2023 guidanceVaccineselskabet Bavarian Nordic var den 15. februar 2023 ude med nyheden om køb af rejsevacciner samt et fase 3 udviklingsprojekt med tilhørende R&D- og produktionsfaciliteter fra Emergent Biosolutions samt offentliggørelse af 2023 guidance.     Mød Bavarian Nordics EVP & CFO Henrik Juuel, der vil give et indblik i ovenstående

Year-End Report 2022

ChromoGenics received order from Vasakronan and enters into cooperation in GermanyQ4 2022 · In Q4 2022, ChromoGenics’ net sales amounted to SEK 3.5 (13.7) million, a decrease of SEK 10.2 million compared to the corresponding quarter in 2021. A weakened market situation and challenges in the production had a negative impact on net sales for the quarter. · ChromoGenics’ operating loss for the fourth quarter of the year amounted to SEK -11.6(-14.7) million, which is an improvement of SEK 3.2 million compared to the corresponding period in 2021. The company’s operating result benefits

HODL SPAC Europe AB: Year-end report 2022

HODL SPAC Europe AB publishes the Year-end report for the period January – December 2022. Please find the report attached or available at the website (www.hodlspac.se). Presented below is a summary of the report. The report in full is only available in Swedish. N.B. this is a translation of the Swedish version, and should there be differences, the Swedish version prevails.”Our first priority is to create long term value for our shareholders. Therefore, we communicated, already at the listing of the share, that we could expand our search beyond the communicated investment criteria. Hence,

Interim report Q4/2022: A year that laid the foundation for growth

Significant events during the quarter Significant events after the quarter · On October 31, the journal · No significant events were reportedRespiratory Research published an in after the end of the quarter.-vitro study from the MedicalUniversity of Innsbruck which showsthat ColdZyme blocks the widespreadand highly transmissible omicronvariants BA.4 and BA.5 from adheringto and infecting human cells.According to the researchers whoconducted the study, this findingmeans the possibility that ColdZymecan be applied to prevent the spreadof SARS-CoV-2.

Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2022

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2022.July - December 2022 · Net sales amounted to 0 (0) SEK. · Operating profit amounted to 237,140 (-143,519) SEK · Profit per average number of shares after tax amounted to 0.01 (-0.01) January - December 2022 · Net sales amounted to 0 (3,991) SEK. · Operating profit amounted to -2,317,061 (-3,503,694) SEK · Profit per average number of shares after tax amounted to -0.15 (-0.24) The report is published at www.clinescientific.com/financial-reports  The company is

NeoDynamics AB (publ) full-year report 2022

Pre-Launch Activities in the US underwayGroup consolidated accounts have been prepared for the fourth quarter, and full year, which includes the consolidation of NeoDynamics AB, NeoDynamics GmbH and NeoDynamics Inc. These are represented in the financial statements as adjusted numbers, and are the comparative figures used for last year. Fourth Quarter 2022 · Revenues amounted to SEK 130 (931) thousand, of which SEK 0 (1,039) thousand were net sales · Net loss amounted to SEK -26,857 (-19,957) thousand. · Loss per share amounted to SEK -0.22 (-0.33). · Cash and cash

Össur hf: Annual General Meeting 10 March 2023

Announcement no. 06/2023 17 February 2023 Annual General Meeting 10 March 2023 Össur hf.'s Annual General Meeting will be held on Friday 10 March 2023 at 9:00 GMT. The Board of Directors has decided to utilize the authorization in Article 17 of Össur’s Articles of Association to have the Annual General Meeting virtual. Enclosed is the convocation, which includes the proposed agenda for the Annual General Meeting and information on shareholders’ participation and registration, shareholders’ rights, voting and proxies, and other practical matters, as well as the proposed

Year-end Report 1 January – 31 December 2022

· 72% growth in customer base and 43% growth in gross order intake · 510(k) clearance received for Episealer® Patellofemoral System, and timetable communicated for 510(k) application for Episealer MTP-System · Strengthening of commercial organization and preparation for US launch ongoing ”Today we are reporting on yet another quarter with clear steps in the right direction. The key metric of the number of surgeons using the Episealer grew by 72% in the quarter, and gross order intake was up by 43%. We clearly experienced positive developments in our commercial activities during the

Year-end report January – December 2022

The period in summary January 1 – December 31, 2022 –      In the end of March the first batch of Strangvac was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac was released for sale in Denmark. –      Intervacc announced on July 20th that the company had received an order for approximately SEK 3 million from Dechra Pharmaceuticals PLC. The order contains vaccine vials for selected countries in Europe. –      Strangvac began being sold late August in the UK, and during the last quarter the sales started

United Bankers Plc announces new long-term financial objectives and focus areas of corporate responsibility

United Bankers Plc STOCK EXCHANGE RELEASE 17 February 2023 at 9:30 EET     United Bankers Plc announces new long-term financial objectives and focus areas of corporate responsibility United Bankers announces its new long-term financial objectives. At the same time, the company publishes information about the key targets and indicators of its new corporate responsibility program. United Bankers’ vision is to be the leading Nordic alternative investment manager and the most trusted partner to its clients. United Bankers’ financial objectives by 2028 are: · to grow its

Nelly.com signs with Ingrid Delivery Platform

Nelly.com — one of the most well-known and loved e-commerce fashion brands in the Nordics — signs with a SaaS Delivery Experience Platform Ingrid to strengthen the delivery offer for their consumers. — We believe that Ingrid makes a great partner for us. Ingrid stands at a forefront of delivery technology, where Nelly.com also strives to be. It's a great match, Stefan Svensson, COO at Nelly.com, says. — The whole setup of Ingrid products will create a better value for us and our consumer base. We want to create the best delivery offer for each purchase and each market,

Hynion Sweden participates in innovation clusters for BioGenGas

Energigas Sweden has been granted funds by the energy authority to run an innovation cluster for sustainable, biogenic energy gases, BioGenGas. Hynion Sweden is one of 24 companies that, together with 4 universities and colleges, were included in the application submitted last autumn.The gas industry has produced a climate roadmap within the framework of Fossil-free Sweden, with the goal that all energy gases used in Sweden must be fossil-free by 2045 at the latest and that the potential for the production of renewable gas must be realized. Examples of BioGene energy gases are biogas,

BioStock: Sensidose is growing and sees opportunities in Finland

The pharmaceutical company Sensidose is growing and sees new opportunities in new markets. According to yesterday's year-end report, sales rose by 10.9 per cent in existing markets. At the same time, the company reported last week that the product Flexilev had been granted a subsidy in Finland. BioStock contacted CEO Jack Spira to learn more about new opportunities in Finland and continued market expansion.Read the interview with Sensidose's CEO Jack Spira at biostock.se: https://www.biostock.se/en/2023/02/sensidose-is-growing-and-sees-opportunities-in-finland/ This is a press release

Share-based payments related to Metso Outotec’s long-term incentive plans

Metso Outotec Corporation’s stock exchange release on February 17, 2023, at 09:15 a.m. EETMetso Outotec’s Board of Directors has decided to convey an estimated total of 737,552 of the company’s treasury shares without consideration to 143 key persons and executives in accordance with the terms and conditions of the Performance Share Plan 2020-2022 (PSP 2020-2022) and Deferred Share Plan 2020-2022 (DSP 2020–2022). The directed share issue is based on an authorization given by the Annual General Meeting held on April 21, 2022. Following the directed share issues on March 15, 2023, the

Report for the fourth quarter 2022 and preliminary year-end accounts

Financial and operating highlights 4Q22 (4Q21 in brackets): · Operating revenues were NOK 3 361 million (NOK 2 713 million) · EBITDA was NOK 1 285 million (NOK 1 108 million) · EBIT was NOK 1 010 million (NOK 902 million) · Net result after tax was NOK 732 million (NOK 637 million) · Dividend proposal of NOK 5.00 per share, (NOK 213 million) · Equity in parent company post proposed dividend NOK 8 071 million (NOK 6 843 million) Segment highlights 4Q22 (4Q21 in brackets): Renewable Energy · EBITDA NOK 1 016 mill. (NOK 1 060 mill.) · Continued high power

Proposal on company name change to Metso Outotec’s Annual General Meeting

Metso Outotec Corporation’s press release on February 17, 2023, at 09:10 a.m. EETIn accordance with the Limited Liability Companies Act, the Board of Directors of Metso Outotec proposes to the Annual General Meeting that the current name of the company is changed to Metso Corporation. The proposal is based on the grounds that the integration of Metso and Outotec, which became effective on July 1, 2020, is completed, and the company’s current strategy focuses on growing a strong unified company that builds on the long history and legacy of its businesses to create significant customer

American Express to make substantial investment at Arlanda

In late March, American Express will temporarily close the Amex Lounge by Pontus at Stockholm Arlanda Airport to carry out an extensive renovation of its lounge space. The refurbishment work is expected to continue until 2024, when the doors to a brand-new Amex Lounge will open. During the renovation, members are invited to the Amex Pop-Up Lounge. Since its start, the Amex Lounge By Pontus in Terminal 5 at Stockholm Arlanda has been a popular hangout for American Express members. On Sunday, March 19, the lounge will close in order to undergo a floor-to-ceiling renovation. In 2024, the

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022     Fourth quarter (October-December 2022) · Operating profit/loss totaled SEK -3,951,799 (-2,142,267). · Loss for the period totaled SEK -3,898,340 (-2,142,267). · Cash flow from operating activities totaled SEK 5,516,307 (-879,846). · Earnings per share before dilution totaled SEK -0.20 (-0,11). Earnings per share after dilution amounted to SEK -0.20 (-0,11). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year)   Period (January-December 2022) · Operating

Notice to the Annual General Meeting of Metso Outotec Corporation

Metso Outotec Corporation’s stock exchange release on February 17, 2023, at 9:05 a.m. EETNotice to the Annual General Meeting of Metso Outotec Corporation Notice is given to the shareholders of Metso Outotec Corporation (“Metso Outotec” or the “Company”) to the Annual General Meeting (the “General Meeting”) to be held on Wednesday, May 3, 2023, at 2.00 p.m. (EEST) at Messukeskus (Siipi entrance) at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. The reception of attendees who have registered for the General Meeting and the distribution of voting tickets will commence at the

Year-end report 2022

IMPROVED PROFIT IN QUARTER DESPITE LOWER VOLUMESOCTOBER – DECEMBER 2022 · Sales volume amounted to 4,124 tonnes (5,503 tonnes) a decline by 25%. · Net sales amounted to SEK 232.0 million (SEK 240.3 million), a decline by 3%. The organic decline was 17%. · Operating profit amounted to SEK 11.3 million (SEK 10.2 million), an increase by 11%. · The adjusted operating profit amounted to SEK 10.9 million (SEK 10.2 million), an increase by 10%. · The operating margin and adjusted operating margin increased to 4.9% (4.2%). · Profit for the period amounted to SEK 8.6 million (

Trading Statement

EnQuest PLC, 17 February 2023 Full year 2022 operations update and 2023 guidance Record free cash flow drives c.$500 million reduction in debt; capital structure reset with debt maturities extended to 2027 Unless otherwise stated, all figures are unaudited, on a Business performance basis and are in US Dollars EnQuest Chief Executive, Amjad Bseisu, commented: "EnQuest delivered strong operational performance and continued to exercise financial discipline, resulting in record free cash flows of over $500 million in 2022. Our net debt has been reduced to around $700 million,

ETTEPLAN 2022: Profitable growth in a changing market

ETTEPLAN OYJ Financial Statement Review February 17, 2023, at 9:00 a.m. (EET) ETTEPLAN 2022: Profitable growth in a changing market Key points October–December 2022   · The Group’s revenue grew by 6.8 per cent and was EUR 91.0 million (10–12/2021: EUR 85.3 million). At comparable exchange rates, revenue increased by 8.6 per cent. · Operating profit (EBITA) grew by 8.5 per cent and was EUR 9.7 (9.0) million, or 10.7 (10.5) per cent of revenue. · Operating profit (EBIT) grew by 7.4 per cent and was EUR 8.4 (7.8) million, or 9.2 (9.2) per cent of revenue. · Operating cash

Exel Composites’ Financial Statements Release Q1–Q4 2022: Stable revenue and higher profitability in 2022 compared to 2021

EXEL COMPOSITES PLC    FINANCIAL STATEMENTS RELEASE    17 February 2023 at 09:00 EETQ4 2022 in brief · Order intake decreased by 15.9% to EUR 25.6 million (Q4 2021: 30.5) · Revenue decreased by 15.1% to EUR 31.0 million (36.5) · Adjusted operating profit stable year-on-year at EUR 0.9 million (1.0), which is 3.0% of revenue (2.8%) · Operating profit decreased to EUR -1.7 million (0.6), which is -5.5% of revenue (1.8%) · Earnings per share amounted to EUR -0.32 (0.04) Q1-Q4 2022 in brief · Order intake decreased by 11.3% to EUR 124.7 million (Q1-Q4 2021: 140.6) ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top